CLINICAL TRIALS AND OBSERVATIONS Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia
نویسندگان
چکیده
Kimmo Porkka,1,2 Perttu Koskenvesa,1,2 Tuija Lundán,1,3 Johanna Rimpiläinen,4 Satu Mustjoki,1,2 Richard Smykla,5 Robert Wild,6 Roger Luo,5 Montserrat Arnan,7 Benoit Brethon,8 Lydia Eccersley,9 Henrik Hjorth-Hansen,10 Martin Höglund,11 Hana Klamova,12 Håvar Knutsen,13 Suhag Parikh,14 Emmanuel Raffoux,15 Franz Gruber,16 Finella Brito-Babapulle,9 Hervé Dombret,15 Rafael F. Duarte,7 Erkki Elonen,2 Ron Paquette,17 C. Michel Zwaan,18,19 and Francis Y. F. Lee5
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
Robin Foà,1 Antonella Vitale,1 Marco Vignetti,2 Giovanna Meloni,1 Anna Guarini,1 Maria Stefania De Propris,1 Loredana Elia,1 Francesca Paoloni,2 Paola Fazi,2 Giuseppe Cimino,1 Francesco Nobile,3 Felicetto Ferrara,4 Carlo Castagnola,5 Simona Sica,6 Pietro Leoni,7 Eliana Zuffa,8 Claudio Fozza,9 Mario Luppi,10 Anna Candoni,11 Ilaria Iacobucci,12 Simona Soverini,12 Franco Mandelli,13 Giovanni Marti...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias
The translocation (9;22) gives rise to the p190Bcr-Abl and p210Bcr-Abl tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph ) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We c...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
1Medizinische Klinik II, Johann Wolfgang Goethe Universität, Frankfurt, Germany; 2Hospital Saint Louis, Paris Cedex, France; 3Istituto di Ematologica E Oncologica Medica, Policlinico S Orsola, Bologna, Italy; 4Department of Hematology, University Hospital, Uppsala, Sweden; 5Clinical Research Centre, Centre Hospitalier Universitaire la Milétrie, Poitiers, France; 6University of Chicago, IL; 7Dip...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Imatinib mesylate, an inhibitor of the BcrAbl tyrosine kinase, has modest activity in refractory/relapsed Philadelphia chromosome (Ph)–positive acute lymphocytic leukemia (ALL). Use of concurrent chemotherapy and imatinib mesylate in newly diagnosed Ph-positive ALL was explored. There were 20 patients who received hyper–CVAD (cyclophosphamide, vincristine, Adriamycin, and dexamethasone) and ima...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)
The Abl kinase inhibitor imatinib mesylate (STI571) has significant and rapid antileukemic activity in Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia (Ph ALL) but such activity is usually of short duration except for a small proportion of patients. To determine the prognostic significance of early Bcr-Abl levels and changes in peripheral blood (PB) and bone marrow (BM), s...
متن کامل